{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:31:43Z","timestamp":1792531903292,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005567","name":"H. Lee Moffitt Cancer Center and Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005567","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.urology.2024.02.033","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T08:14:13Z","timestamp":1710144853000},"page":"106-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cost-utility of Initial Management of High-grade T1 Bladder Cancer With Intravesical BCG vs Immediate Radical Cystectomy"],"prefix":"10.1016","volume":"187","author":[{"given":"Heather L.","family":"Huelster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil T.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Facundo","family":"Davaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Mahrukh Hussain","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngchul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2024.02.033_bib1","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/00005650-199508000-00007","article-title":"Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis","volume":"33","author":"Riley","year":"1995","journal-title":"Med Care"},{"key":"10.1016\/j.urology.2024.02.033_bib2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.6004\/jnccn.2015.0123","article-title":"Role of repeat resection in non-muscle-invasive bladder cancer","volume":"13","author":"Herr","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2024.02.033_bib3","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1464-410X.2010.09628.x","article-title":"Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort","volume":"107","author":"Svatek","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2024.02.033_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/106689690501300203","article-title":"The 2004 WHO classification of bladder tumors: a summary and commentary","volume":"13","author":"Montironi","year":"2005","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.urology.2024.02.033_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0094-0143(03)00060-0","article-title":"Evaluation and follow-up strategies for superficial bladder cancer","volume":"30","author":"Donat","year":"2003","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2024.02.033_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib8","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2024.02.033_bib10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib12","doi-asserted-by":"crossref","first-page":"39 e11","DOI":"10.1016\/j.urolonc.2019.10.016","article-title":"Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer","volume":"38","author":"Sloan","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2024.02.033_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.urology.2006.03.062","article-title":"Clinical model of lifetime cost of treating bladder cancer and associated complications","volume":"68","author":"Avritscher","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.02.033_bib14","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s12325-020-01616-3","article-title":"The impact of progression on healthcare resource utilization and costs among patients with high-grade non-muscle invasive bladder cancer after bacillus calmette-guerin therapy: a retrospective SEER-medicare analysis","volume":"38","author":"Yang","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.urology.2024.02.033_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2024.02.033_bib16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1525-1497.1997.07107.x","article-title":"Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on cost-effectiveness in health and medicine","volume":"12","author":"Mandelblatt","year":"1997","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.urology.2024.02.033_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urology.2024.02.033_bib19","unstructured":"Auget J.L.B.N.Mesbah M.Molenberghs G., editors. International Conference on Statistics in Health Sciences AJ-L. Advances in statistical methods for the health sciences: applications to cancer and AIDS studies, genome sequence analysis, and survival analysis. Boston, MA. 2007; Birkhauser."},{"key":"10.1016\/j.urology.2024.02.033_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.urology.2024.02.033_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.euo.2023.01.011","article-title":"Cost effectiveness of treatment sequences in advanced renal cell carcinoma","volume":"6","author":"Mason","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urology.2024.02.033_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/2090598X.2021.1874628","article-title":"Assessment of the oncological outcomes of three different bacillus Calmette-Guerin strains in patients with high-grade T1 non-muscle-invasive bladder cancer","volume":"19","author":"Nowak","year":"2021","journal-title":"Arab J Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib24","doi-asserted-by":"crossref","first-page":"5 e9","DOI":"10.1016\/j.urolonc.2019.05.018","article-title":"Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer","volume":"38","author":"Daniels","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2024.02.033_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043266","article-title":"Short-term morbidity and mortality following radical cystectomy: a systematic review","volume":"11","author":"Maibom","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.urology.2024.02.033_bib28","first-page":"28","article-title":"Urinary diversions for radical cystectomy: a review of complications and their management","volume":"5","author":"Tinoco","year":"2021","journal-title":"Mini-invasive Surg"},{"key":"10.1016\/j.urology.2024.02.033_bib29","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/cncr.21896","article-title":"Quality of life in long-term survivors of bladder cancer","volume":"106","author":"Allareddy","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2024.02.033_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrurol.2014.151","article-title":"Sexual dysfunction after cystectomy and urinary diversion","volume":"11","author":"Modh","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2012.08.015","article-title":"Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study","volume":"32","author":"Bruins","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2024.02.033_bib33","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib35","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2024.02.033_bib36","unstructured":"Organization WH. Life Expectancy and Life Tables. 2022."},{"key":"10.1016\/j.urology.2024.02.033_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1475-6773.12612","article-title":"Adjusting health expenditures for inflation: a review of measures for health services research in the United States","volume":"53","author":"Dunn","year":"2018","journal-title":"Health Serv Res"},{"key":"10.1016\/j.urology.2024.02.033_bib38","unstructured":"Centers for Medicare and Medicaid Services. Physician Fee Schedule."},{"key":"10.1016\/j.urology.2024.02.033_bib39","unstructured":"Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality.;Rockville, MD."},{"key":"10.1016\/j.urology.2024.02.033_bib40","unstructured":"Centers for Medicare and Medicaid Services. Medicare Part B Drug Average Sales Price: 2021 ASP Drug Pricing Files."},{"key":"10.1016\/j.urology.2024.02.033_bib41","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2024.02.033_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040284","article-title":"Optimal management of high-risk T1G3 bladder cancer: a decision analysis","volume":"4","author":"Kulkarni","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.urology.2024.02.033_bib43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12913-015-0772-9","article-title":"Acute and chronic impact of cardiovascular events on health state utilities","volume":"15","author":"Matza","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.urology.2024.02.033_bib44","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JU.0000000000001023","article-title":"Cost-effectiveness of maintenance bacillus Calmette-Guerin for intermediate and high risk nonmuscle invasive bladder cancer","volume":"204","author":"Sharma","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib45","series-title":"Cost-effectiveness in Health and Medicine","year":"2016"},{"key":"10.1016\/j.urology.2024.02.033_bib46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/j.semss.2009.08.003","article-title":"Decision analysis and cost-effectiveness analysis","volume":"21","author":"Ryder","year":"2009","journal-title":"Semin Spine Surg"},{"key":"10.1016\/j.urology.2024.02.033_bib47","first-page":"211","article-title":"Application of cost-effectiveness analysis to multiple products: a practical guide","volume":"8","author":"Bala","year":"2002","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.urology.2024.02.033_bib48","doi-asserted-by":"crossref","first-page":"E601","DOI":"10.1001\/amajethics.2021.601","article-title":"How should willingness-to-pay values of quality-adjusted life-years be updated and according to whom?","volume":"23","author":"Menzel","year":"2021","journal-title":"AMA J Ethics"},{"key":"10.1016\/j.urology.2024.02.033_bib49","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.urology.2024.02.033_bib50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00019053-199813050-00002","article-title":"The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data","volume":"13","author":"Desgagne","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.urology.2024.02.033_bib51","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","article-title":"The burden of bladder cancer care: direct and indirect costs","volume":"24","author":"Mossanen","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib52","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews","volume":"12","author":"Lee","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.urology.2024.02.033_bib53","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.urology.2024.02.033_bib54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.urology.2007.10.056","article-title":"Clinical model of cost of bladder cancer in the elderly","volume":"71","author":"Cooksley","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.02.033_bib55","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1002\/cncr.24634","article-title":"Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer","volume":"115","author":"Kulkarni","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2024.02.033_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejso.2015.10.001","article-title":"Systematic review and meta-analysis of non RCT's on health related quality of life after radical cystectomy using validated questionnaires: Better results with orthotopic neobladder versus ileal conduit","volume":"42","author":"Cerruto","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.urology.2024.02.033_bib57","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eururo.2018.04.030","article-title":"Randomized trial comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: oncologic outcomes","volume":"74","author":"Bochner","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.02.033_bib58","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial","volume":"391","author":"Parekh","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2024.02.033_bib59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ucl.2013.01.004","article-title":"The costs of non-muscle invasive bladder cancer","volume":"40","author":"James","year":"2013","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2024.02.033_bib60","doi-asserted-by":"crossref","first-page":"293 e215","DOI":"10.1016\/j.urolonc.2023.01.020","article-title":"The effect of treatment on work productivity in patients with bladder cancer","volume":"41","author":"Ahlschlager","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2024.02.033_bib61","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1159\/000524098","article-title":"Quality of life, efficacy, and safety of sequential intravesical gemcitabine + docetaxel versus bcg for non-muscle invasive urinary bladder cancer: a pilot study","volume":"106","author":"Pareek","year":"2022","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2024.02.033_bib62","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guerin-Naive high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524001262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524001262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T23:41:53Z","timestamp":1720222913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429524001262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":62,"alternative-id":["S0090429524001262"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2024.02.033","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-utility of Initial Management of High-grade T1 Bladder Cancer With Intravesical BCG vs Immediate Radical Cystectomy","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2024.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}